LinkMed: Interim report January – September, 2008

Group financial development July – September
Following the acquisition of 100 percent of the shares of Olerup SSP AB, LinkMed is now reported as a group.
• Net sales totaled SEK 16.8 million
• Results of investing activities were SEK 0 million
• Net income after tax was SEK 6.4 million
• Basic earnings per share was SEK 0.73
• Equity per share was SEK 57.6
• Equity/assets ratio was 69 percent

Parent company financial development January– September
• Results of investing activities were SEK 0 million (0)
• Other revenue totaled SEK 2.9 million (3.7)
• Net loss after tax was SEK 9.3 million (-5.9)

Key events in the third quarter
• LinkMed acquires 100 percent of Olerup SSP AB
• AbSorber receives FDA clearance to sell XM-ONE® in the U.S.
• LinkMed participates in AnaMar Medical’s new share issue with SEK 10 million

CEO Ingemar Lagerlöf’s commentary on the third quarter 2008:
”Following the acquisition of the transplantation sector company Olerup SSP AB in the third quarter, LinkMed is now a group, with Olerup SSP as a wholly owned subsidiary. The acquisition gives us the opportunity to, in collaboration with our transplantation sector company AbSorber, to build a unique and considerably larger transplantation sector company with a strong future pipeline. The acquisition strengthens LinkMed’s financial position with a strong cash flow. Through the acquisition of Olerup SSP, LinkMed reports profit in the third quarter.”

For additional information please contact:
Ingemar Lagerlöf, CEO LinkMed, cell +46 8 (0)70-873 2733 or e-mail ingemar.lagerlof@linkmed.se
Okee Williams, Portfolio Manager, cell +46 (0)70- 600 5364 or e-mail okee.williams@linkmed.se